Cataflam: profile and news

Aspen's African domination  Feb 28, 2006
Aspen launched 20 new generic products during the period under review, including substitutes for Ritalin, Myprodol and Cataflam. ... - Moneyweb,

NSAIDs Somewhat Better Than Tylenol for Osteoarthritis, Review ...  Jan 24, 2006
...traditional NSAIDs such as ibuprofen (sold as Advil, Nuprin, Haltran, Medipren, Motrin, Midol, Brufen and Genpril), diclofenac (sold as Cataflam, Voltaren and ... - Health Behavior News Service

Preliminary Phase IIb Study Shows Dyloject(TM) Relieves ...  Jan 23, 2006
Diclofenac, the same active ingredient in Dyloject(TM), Voltaren(R), Cataflam(R) and Voltarol(R), is a leading analgesic for the treatment of moderate-to ... - Business Wire (press release),

Preliminary Phase IIb Study Shows Dyloject™ Relieves ...  Jan 23, 2006
Diclofenac, the same active ingredient in Dyloject(TM), Voltaren®, Cataflam® and Voltarol®, is a leading analgesic for the treatment of moderate-to-severe ... - dBusinessNews New York (press release),

No evidence that COX-2 inhibitors provide greater gastroprotection  Dec 9, 2005
...were reduced after adjusting for other factors, but remained significantly increased for Naproxen ( Aleve/Naprosyn ), Diclofenac ( Cataflam/Voltaren ), and ... - Xagena.it,

OTC Painkillers Raise Death Risk After Heart Attack  Nov 13, 2005
...taking more than 25 milligrams a day of Vioxx (rofecoxib) had a 5.03 times higher risk; those taking more than 100 milligrams a day of Cataflam and Voltaren ... - Forbes

NSAIDs Increase Death Risk after Heart Attack  Nov 16, 2005
...taking more than 25 mg of Vioxx (rofecoxib) had a 5.03 times increased risk, and those taking more than more than 100 milligrams a day of Cataflam and Voltaren ... - HeartZine,

Sleep deprivation makes driving dangerous  Sep 18, 2005
They include diclofenac (Cataflam, Voltaren), etodolac (Lodine), fenoprofen (Nalfon), ibuprofen (Motrin, Advil), indomethacin (Indocin), nabumetone (Relafen ... - Houston Chronicle,

Final Results of Phase II/III Study Show Dyloject(TM) Has Superior ...  Sep 16, 2005
Diclofenac, the same active ingredient in Dyloject(TM), Voltaren(R), Cataflam(R) and Voltarol(R), is a leading analgesic for the treatment of moderate-to ... - Genetic Engineering News,

IDDS to Host Conference Call to Discuss Positive Pivotal Phase II ...  Jul 25, 2005
Diclofenac, the same active ingredient in Dyloject(TM), Voltaren(R), Cataflam(R) and Voltarol(R), is a leading analgesic, with a demonstrated history of ... - Business Wire (press release)

Pivotal Phase II/III Study Shows Dyloject(TM) Significantly ...  Jul 12, 2005
Diclofenac, the same active ingredient in Dyloject(TM), Voltaren(R), Cataflam(R) and Voltarol(R), is a leading analgesic for the treatment of moderate-to ... - Business Wire (press release)

Pivotal Phase II/III Study Shows Dyloject™ Significantly Reduces ...  Jul 13, 2005
Diclofenac, the same active ingredient in Dyloject™, Voltaren®, Cataflam® and Voltarol®, is a leading analgesic for the treatment of moderate-to-severe ... - dBusinessNews New York (press release) <**results**>

Study: Pain Relievers Increasing Heart Attack Risk  Jun 9, 2005
32 percent. The Drug Diclofenac, which is sold as Cataflam and Voltaren, more than doubled the risk of heart attack. The findings ... - CBS 5

Study Suggests More Pain Killers Put Patients at Risk  Jun 10, 2005
Vioxx, which was taken off the market, increased risk by 32%. And for Diclofenac, sold as Cataflam and Voltaren, the risk rose by over fifty percent. ... - KSL-TV

Most Painkillers Up Heart Attack Risk  Jun 17, 2005
NSAIDs. There was a 2 percent risk of heart attack with 150 milligrams a day or less of diclofenac (Arthrotec, Cataflam, Voltaren). ... - FOX News

Study: Pain Relievers Increasing Heart Attack Risk  Jun 9, 2005
32 percent. The Drug Diclofenac, which is sold as Cataflam and Voltaren, more than doubled the risk of heart attack. The findings ... - CBS 5,

Study Suggests More Pain Killers Put Patients at Risk  Jun 10, 2005
Vioxx, which was taken off the market, increased risk by 32%. And for Diclofenac, sold as Cataflam and Voltaren, the risk rose by over fifty percent. ... - KSL-TV,

Most Painkillers Up Heart Attack Risk  Jun 17, 2005
NSAIDs. There was a 2 percent risk of heart attack with 150 milligrams a day or less of diclofenac (Arthrotec, Cataflam, Voltaren). ... - FOX News

Ibuprofen increases risk of heart attacks  Jun 9, 2005
...see if and when they had been prescribed NSAIDS, which also include naproxen, which is found in Aleve and Naprelan; diclofenac - found in Cataflam and Voltaren ... - Scotsman,

Like Vioxx, Ibuprofen May Up Heart Attack Risk  Jun 9, 2005
...three years. Diclofenac (brand names including Arthrotec, Cataflam, and Voltaren) increased heart attack risk by 55%. Naproxen (brand ... - WebMD

THE KILLER PAINKILLER  Jun 10, 2005
The group found another popular drug Diclofenac - also known as Cataflam and Voltaren - increased heart attack risk by 55 per cent. ... - Glasgow Daily Record,

Bad News for Cox-2 Inhibitors Was Good News for Mobic  Jun 3, 2005
...beneficiary of the Vioxx withdrawal, there has also been a bump in prescriptions for other less expensive NSAIDs such Voltaran and Cataflam (diclofenac) which ... - MedPage Today,

New Warning on Painkillers  Jun 10, 2005
The findings published in the British Medical Journal showed that, for people over 65 taking diclofenac (Cataflam and Voltaren), one extra patient in every 521 ... - Red Herring,

Effects of FDA's Decisions  Apr 8, 2005
Included are Voltaren, Cataflam, Arthrotec, Dolobid, Lodine, Nalfon, Ansaid, Indocin, Indomethegan, Toradol, Ponstel, Mobic, Relafen, Daypro, Feldene, Disalcid ... - Charlotte Observer

Painkiller Bextra pulled from shelves  Apr 8, 2005
The drugs include Voltaren, Cataflam, Arthrotec, Dolobid, Lodine, Nalfon, Ansaid, Indocin, Indomethegan, Toradol, Ponstel, Mobic, Relafen, Daypro, Feldene ... - Miami Herald,

Side Effects Of The Drug Scares  Feb 28, 2005
In fact, epidemiological studies suggest that some of those drugs, such as diclofenac (Cataflam and Voltaren), meloxicam (Mobic), or even over-the-counter ... - BusinessWeek

Pfizer And Merck Face The Jury  Feb 17, 2005
...such staples as Aleve, Motrin, Advil and diclofenac--which is available as the Novartis (nyse: NVS - news - people ) branded drug Cataflam--might harm the ... - Forbes

How Celebrex Could Recover Its Sheen  Feb 23, 2005
Advil and Johnson & Johnson's (nyse: JNJ - news - people ) Motrin--and diclofenac, marketed by Novartis (nyse: NVS - news - people ) as Cataflam, might be ... - Forbes

Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.

Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs. Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.

Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporineís nephrotoxicity. Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs. They should be observed closely, particularly if renal function is impaired. In the case of digoxin, serum levels should be monitored.

Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels. In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.

Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents. There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents. Both hypo- and hyperglycemic effects have been reported. A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patientís response to insulin or oral hypoglycemic agents.

Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.

Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac. Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.

Protein Binding

In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin. Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.

Drug/Laboratory Test Interactions

Effect on Blood Coagulation: Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII. Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers. The mean changes were observed to be less than 1 second in both instances, however, and are unlikely to be clinically important. Diclofenac is a prostaglandin synthetase inhibitor, however, and all drugs that inhibit prostaglandin synthesis interfere with platelet function to some degree; therefore, patients who may be adversely affected by such an action should be carefully observed.